RecombinantRabMAb

Recombinant Anti-Urokinase antibody [EPR6273] (ab133563)

Submit a review Q&A (1)References (6)
Western blot - Anti-Urokinase antibody [EPR6273] (ab133563)
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Urokinase antibody [EPR6273] (ab133563)
  • Western blot - Anti-Urokinase antibody [EPR6273] (ab133563)
  • Western blot - Anti-Urokinase antibody [EPR6273] (ab133563)
  • OI-RD Scanning - Anti-Urokinase antibody [EPR6273] (ab133563)
  • Anti-Urokinase antibody [EPR6273] (ab133563)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR6273] to Urokinase
  • Suitable for: WB, IHC-P
  • Reacts with: Human

Conjugates logo Related conjugates and formulations

Carrier Free

Overview

  • Product name

    Anti-Urokinase antibody [EPR6273]
    See all Urokinase primary antibodies

  • Description

    Rabbit monoclonal [EPR6273] to Urokinase

  • Host species

    Rabbit

  • Tested applications

    Suitable for: WB, IHC-Pmore details
    Unsuitable for: Flow Cyt or ICC/IF

  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse, Rat

  • Immunogen

    Synthetic peptide within Human Urokinase aa 50-150. The exact sequence is proprietary.
    Database link: P00749

  • Positive control

    • WB: PC-3, LnCaP and MCF7 cell lysates. IHC-P: Human kidney tissue.

  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

Properties

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab133563 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
1/1000. Predicted molecular weight: 49 kDa.

For unpurified use at 1/100.
IHC-P
1/150. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

See IHC antigen retrieval protocols.
Notes
WB
1/1000. Predicted molecular weight: 49 kDa.

For unpurified use at 1/100.
IHC-P
1/150. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

See IHC antigen retrieval protocols.
Application notes
Is unsuitable for Flow Cyt or ICC/IF.

Target

  • Function

    Specifically cleave the zymogen plasminogen to form the active enzyme plasmin.

  • Tissue specificity

    Expressed in the prostate gland and prostate cancers.

  • Sequence similarities

    Belongs to the peptidase S1 family.
    Contains 1 EGF-like domain.
    Contains 1 kringle domain.
    Contains 1 peptidase S1 domain.

  • Post-translational
    modifications

    Phosphorylation of Ser-158 and Ser-323 abolishes proadhesive ability but does not interfere with receptor binding.

  • Cellular localization

    Secreted.
  • Information by UniProt

  • Database links

    see all

  • Alternative names

    • ATF antibody
    • ATF uPA antibody
    • BDPLT5 antibody
    • Plasminogen activator antibody
    • Plasminogen activator urinary antibody
    • Plasminogen activator urokinase antibody
    • PLAU antibody
    • QPD antibody
    • u PA antibody
    • U plasminogen activator antibody
    • u-PA antibody
    • U-plasminogen activator antibody
    • uPA antibody
    • URK antibody
    • UROK_HUMAN antibody
    • Urokinase plasminogen activator antibody
    • Urokinase type plasminogen activator antibody
    • Urokinase type plasminogen activator precursor antibody
    • Urokinase-type plasminogen activator chain B antibody
    see all

Images

  • Western blot - Anti-Urokinase antibody [EPR6273] (ab133563)
    Western blot - Anti-Urokinase antibody [EPR6273] (ab133563)
    All lanes : Anti-Urokinase antibody [EPR6273] (ab133563) at 1/100 dilution (unpurified)

    Lane 1 : LnCap cell lysate
    Lane 2 : PC-3 cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

    Predicted band size: 49 kDa
    Observed band size: 49 kDa



    Blocking buffer and concentration: 5% NFDM/TBST.

    Diluting buffer and concentration: 5% NFDM /TBST.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Urokinase antibody [EPR6273] (ab133563)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Urokinase antibody [EPR6273] (ab133563)

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue labelling Urokinase with purified ab133563 at 1/150. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Negative control using PBS instead of primary antibody. Counterstained with Hematoxylin.

  • Western blot - Anti-Urokinase antibody [EPR6273] (ab133563)
    Western blot - Anti-Urokinase antibody [EPR6273] (ab133563)
    All lanes : Anti-Urokinase antibody [EPR6273] (ab133563) at 1/1300 dilution (purified)

    Lane 1 : LnCaP cell lysate
    Lane 2 : PC-3 cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

    Predicted band size: 49 kDa
    Observed band size: 49 kDa



    Blocking buffer and concentration: 5% NFDM/TBST.

    Diluting buffer and concentration: 5% NFDM /TBST.

  • Western blot - Anti-Urokinase antibody [EPR6273] (ab133563)
    Western blot - Anti-Urokinase antibody [EPR6273] (ab133563)
    All lanes : Anti-Urokinase antibody [EPR6273] (ab133563) at 1/1000 dilution (unpurified)

    Lane 1 : PC-3 cell lysate
    Lane 2 : LnCaP cell lysate
    Lane 3 : MCF7 cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : HRP-conjugated goat anti-rabbit IgG at 1/2000 dilution

    Developed using the ECL technique.

    Predicted band size: 49 kDa

  • OI-RD Scanning - Anti-Urokinase antibody [EPR6273] (ab133563)
    OI-RD Scanning - Anti-Urokinase antibody [EPR6273] (ab133563)
    Equilibrium disassociation constant (KD)
    Learn more about KD

    Click here to learn more about KD
  • Anti-Urokinase antibody [EPR6273] (ab133563)
    Anti-Urokinase antibody [EPR6273] (ab133563)

References (6)

Publishing research using ab133563? Please let us know so that we can cite the reference in this datasheet.

ab133563 has been referenced in 6 publications.

  • Abufaraj M  et al. The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. Urol Oncol N/A:N/A (2020). PubMed: 32381392
  • Burchall GF  et al. Expression of the plasminogen system in the physiological mouse ovary and in the pathological polycystic ovary syndrome (PCOS) state. Reprod Biol Endocrinol 17:33 (2019). PubMed: 30878040
  • Yang K  et al. Identification of SERPINE1, PLAU and ACTA1 as biomarkers of head and neck squamous cell carcinoma based on integrated bioinformatics analysis. Int J Clin Oncol N/A:N/A (2019). PubMed: 30937621
  • Cammalleri M  et al. The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: New pre-clinical evidence in the rd10 mouse model. J Cell Mol Med 23:5176-5192 (2019). PubMed: 31251468
  • Zhao L  et al. Alterations in complement and coagulation pathways of human placentae subjected to in vitro fertilization and embryo transfer in the first trimester. Medicine (Baltimore) 98:e17031 (2019). PubMed: 31689742
  • Ye S  et al. Thrombosis recanalization by paeoniflorin through the upregulation of urokinase-type plasminogen activator via the MAPK signaling pathway. Mol Med Rep 13:4593-8 (2016). WB ; Human . PubMed: 27082639

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

Question

Urokinase is synthesized as a zymogen form (app. 54 kDa), and is activated by proteolytic cleavage. The two resulting chains are kepttogether by a disulfide bond. So when i reduce my samples for western blotting I cleave the disulfide band and get two bands of app 18 and 33 kDa. So why do you only get one band of app. 49 kDa with this antibody. Shouldn´t I get two bands; the zymogen form and one of the smaller bands (18 or 33 kDa, depending on where the epitope is)?

Read More
Answer

According to the literature, the ˜54/49kD can be detected under reducing conditions and it could represent the single chain pro-uPA. Also, looking at some of the literatures’ data, the detection of the pro-uPA, 18 and 33kD bands will vary from one sample to another.

Furthermore, it’s possible that the reducing agent could make a difference too. For example, to test this antibody, we used BME, which is a weaker reducing agent than DTT and so this may account for the single band at 49 kDa being observed.

Read More

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com